| Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update SA Scott, K Sangkuhl, CM Stein, JS Hulot, JL Mega, DM Roden, TE Klein, ... Clinical Pharmacology & Therapeutics 94 (3), 317-323, 2013 | 1010 | 2013 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake … JK Hicks, JR Bishop, K Sangkuhl, DJ Müller, Y Ji, SG Leckband, ... Clinical Pharmacology & Therapeutics 98 (2), 127-134, 2015 | 947 | 2015 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing JA Johnson, L Gong, M Whirl‐Carrillo, BF Gage, SA Scott, CM Stein, ... Clinical Pharmacology & Therapeutics 90 (4), 625-629, 2011 | 765 | 2011 |
| Multi-ethnic genome-wide association study for atrial fibrillation C Roselli, MD Chaffin, LC Weng, S Aeschbacher, G Ahlberg, CM Albert, ... Nature genetics 50 (9), 1225-1233, 2018 | 602 | 2018 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics‐guided warfarin dosing: 2017 update JA Johnson, KE Caudle, L Gong, M Whirl‐Carrillo, CM Stein, SA Scott, ... Clinical Pharmacology & Therapeutics 102 (3), 397-404, 2017 | 596 | 2017 |
| Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy SA Scott, K Sangkuhl, EE Gardner, CM Stein, JS Hulot, JA Johnson, ... Clinical Pharmacology & Therapeutics 90 (2), 328-332, 2011 | 570 | 2011 |
| Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) KE Caudle, HM Dunnenberger, RR Freimuth, JF Peterson, JD Burlison, ... Genetics in Medicine 19 (2), 215-223, 2017 | 473 | 2017 |
| Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process K E Caudle, T E Klein, J M Hoffman, D J Muller, M Whirl-Carrillo, L Gong, ... Current drug metabolism 15 (2), 209-217, 2014 | 430 | 2014 |
| Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and … KE Caudle, K Sangkuhl, M Whirl‐Carrillo, JJ Swen, CE Haidar, TE Klein, ... Clinical and translational science 13 (1), 116-124, 2020 | 424 | 2020 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy B Moriyama, AO Obeng, J Barbarino, SR Penzak, SA Henning, SA Scott, ... Clinical Pharmacology & Therapeutics 102 (1), 45-51, 2017 | 340 | 2017 |
| Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation IE Christophersen, M Rienstra, C Roselli, X Yin, B Geelhoed, J Barnard, ... Nature genetics 49 (6), 946-952, 2017 | 314 | 2017 |
| Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study MA Perera, LH Cavallari, NA Limdi, ER Gamazon, A Konkashbaev, ... The Lancet 382 (9894), 790-796, 2013 | 304 | 2013 |
| Personalizing medicine with clinical pharmacogenetics SA Scott Genetics in medicine 13 (12), 987-995, 2011 | 268 | 2011 |
| Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis G Cayla, JS Hulot, SA O’Connor, A Pathak, SA Scott, Y Gruel, J Silvain, ... Jama 306 (16), 1765-1774, 2011 | 265 | 2011 |
| Design and anticipated outcomes of the eMERGE‐PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems LJ Rasmussen‐Torvik, SC Stallings, AS Gordon, B Almoguera, ... Clinical Pharmacology & Therapeutics 96 (4), 482-489, 2014 | 254 | 2014 |
| PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19 SA Scott, K Sangkuhl, AR Shuldiner, JS Hulot, CF Thorn, RB Altman, ... Pharmacogenetics and genomics 22 (2), 159-165, 2012 | 227 | 2012 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing JJ Lima, CD Thomas, J Barbarino, Z Desta, SL Van Driest, N El Rouby, ... Clinical Pharmacology & Therapeutics 109 (6), 1417-1423, 2021 | 213 | 2021 |
| Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update CR Lee, JA Luzum, K Sangkuhl, RS Gammal, MS Sabatine, CM Stein, ... Clinical pharmacology & therapeutics 112 (5), 959-967, 2022 | 210 | 2022 |
| Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups SA Scott, R Khasawneh, I Peter, R Kornreich, RJ Desnick Pharmacogenomics 11 (6), 781-791, 2010 | 191 | 2010 |
| Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting LV Kalman, JAG Agúndez, ML Appell, JL Black, GC Bell, S Boukouvala, ... Clinical Pharmacology & Therapeutics 99 (2), 172-185, 2016 | 190 | 2016 |
